#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypocalcaemia Trigeminal neuralgia Hodgkin's disease Alternating hemiplegia of childhood Metastases to central nervous system Tuberous sclerosis complex Inborn error of metabolism Hyperadrenocorticism CDKL5 deficiency disorder Chronic myelomonocytic leukaemia Castleman's disease Alport's syndrome Non-Hodgkin's lymphoma Congenital nephrogenic diabetes insipidus Ureteric cancer More trials…

    Learn about Rare Diseases

    Alexander disease Osteosarcoma metastatic – Basic Information Medulloblastoma recurrent – Diagnostics Soft tissue sarcoma – Treatment Activated PI3 kinase delta syndrome – Treatment Mantle cell lymphoma – Diagnostics Piriformis syndrome – Trials in Disease Bronchiolitis obliterans syndrome – Trials in Disease X-linked lymphoproliferative syndrome – Trials in Disease Choroid melanoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vidofludimus Calcium BLEXIMENIB Levothyroxine Sodium Incb099280 Betamethasone Valerate Fluorescein Sodium Pelacarsen Df1001 Acoramidis Pralatrexate MOLNUPIRAVIR SODIUM IBANDRONATE Paraffin White Soft Umeclidinium Thiamazole LUNSEKIMIG Dolutegravir Sodium Chloride Solution 0.9% Platelet Concentrate Tamsulosin Hydrochloride More therapies…

    Learn about Your Condition

    Hyperhidrosis Large cell lung cancer stage 0 Insomnia Pulmonary congestion Alveolar rhabdomyosarcoma Peptostreptococcus infection Diabetic foot infection Haemolytic uraemic syndrome Double hit lymphoma Graft versus host disease Peritoneal abscess Thalassaemia Oesophageal adenocarcinoma Polymyalgia rheumatica Macular degeneration More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. National Oncology Institute

National Oncology Institute

Klenova 1, Bratislava, 833 10, Slovakia

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Czechia Denmark France Germany +9

  • Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Ibrutinib
    • Lisaftoclax
    Belgium Bulgaria Czechia France Germany Hungary +5

  • Study Comparing Sacituzumab Govitecan to Physician’s Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Gemcitabine
    • Paclitaxel
    Austria Belgium Czechia France Germany Hungary +6

  • Study of RO7247669 at Different Doses for People with Previously Untreated Advanced Melanoma that Cannot be Removed by Surgery or Has Spread

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Ro7247669
    Czechia Greece Poland Slovakia Spain

  • Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Capecitabine
    Belgium Bulgaria Czechia Denmark Finland Germany +7

  • Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • Follicular lymphoma
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Belgium Bulgaria Croatia Czechia Denmark France +11

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
    Belgium Bulgaria Czechia Finland Germany Greece +5

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system melanoma
    • Gastrointestinal melanoma
    • Malignant melanoma
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Ipilimumab
    Germany Italy Poland Slovakia Spain

  • Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Fulvestrant
    • Letrozole
    • Pf-07220060 Monohydrate
    Czechia Slovakia

  • Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Czechia France Germany Hungary Ireland +5

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!